Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors
The genetic concept of synthetic lethality, in which the combination or synthesis of mutations
in multiple genes results in cell death, provides a framework to design novel therapeutic …
in multiple genes results in cell death, provides a framework to design novel therapeutic …
An update on PARP inhibitors—moving to the adjuvant setting
A Sonnenblick, E De Azambuja, HA Azim Jr… - Nature reviews Clinical …, 2015 - nature.com
Inhibition of poly (ADP-ribose) polymerase (PARP) enzymes is a potential synthetic lethal
therapeutic strategy in cancers harbouring specific DNA-repair defects, including those …
therapeutic strategy in cancers harbouring specific DNA-repair defects, including those …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
PARP inhibitors in the management of breast cancer: current data and future prospects
L Livraghi, JE Garber - BMC medicine, 2015 - Springer
Abstract Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA …
[HTML][HTML] PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
JM Lee, JA Ledermann, EC Kohn - Annals of oncology, 2014 - Elsevier
Poly (ADP-ribose) polymerase inhibitors (PARPis) have shown promising activity in patients
with BRCA1/2 mutation-associated (BRCA1/2 MUT+) ovarian and breast cancers …
with BRCA1/2 mutation-associated (BRCA1/2 MUT+) ovarian and breast cancers …
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
GE Konecny, RS Kristeleit - British journal of cancer, 2016 - nature.com
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death
in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by …
in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by …
[HTML][HTML] DNA repair in prostate cancer: biology and clinical implications
Context For more precise, personalized care in prostate cancer (PC), a new classification
based on molecular features relevant for prognostication and treatment stratification is …
based on molecular features relevant for prognostication and treatment stratification is …
Applying synthetic lethality for the selective targeting of cancer
DP McLornan, A List, GJ Mufti - New England Journal of Medicine, 2014 - Mass Medical Soc
Applying Synthetic Lethality for the Selective Targeting of Cancer | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy
YQ Wang, PY Wang, YT Wang, GF Yang… - Journal of medicinal …, 2016 - ACS Publications
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised …
JA Ledermann, AM Oza, D Lorusso… - The Lancet …, 2020 - thelancet.com
Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-
free survival versus placebo. Here, we report prespecified, investigator-assessed …
free survival versus placebo. Here, we report prespecified, investigator-assessed …